ClinicalTrials.gg
Not yet recruitingNCT07665099Updated Jun 24, 2026

The Effect of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Oral and Maxillofacial Surgery

An interventional study of esketamine and Normal Saline in Perioperative Neurocognitive Disorders, sponsored by Xijing Hospital. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Neurocognitive Disorders with a site in China — 13 open to participants now, 14 under way, 1 of them phase 3. Neurocognitive Disorders · China.

Planned enrollment
10th of 15
98 · median 264
Started
2026
with 5 others
No phase
9 of 22
6 open now
Primary completion
2027-01
later than 3 of 13 live
Registered
19th of 22
by date

Among the 22 studies in Neurocognitive Disorders with a site in China, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is one of 6 that started in 2026, is one of 9 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 19th registered.

Neurocognitive Disorders

275 studies on the registry are indexed under Neurocognitive Disorders; 91 are open to participants now.

Browse Neurocognitive Disorders studies →

Open to participants now

13 of the 22 studies in Neurocognitive Disorders with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 61 Neurocognitive Disorders studies recruiting now, 38 (62%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Neurocognitive Disorders with a site in China, or all of them as a file.
02

Study summary

Esketamine is a common anesthetic adjuvant. Previous studies have shown that it may have protective effects on the brain. This study aims to investigate whether esketamine can improve cognitive function recovery in elderly patients (aged 60 years and older) undergoing oral and maxillofacial surgery.

Participants will be randomly assigned to receive either esketamine or a placebo (normal saline) during anesthesia. Neither the participants nor the researchers will know which treatment is given.

Cognitive function will be assessed using standardized tests before surgery and at 1, 3, 7, and 15 days after surgery. Sleep quality, pain scores, emotional status, and adverse events will also be recorded. Blood samples will be collected to explore potential mechanisms.

The study is expected to enroll approximately 98 participants at the Third Affiliated Hospital of Air Force Medical University in Xi'an, China. Participation will last about 16 days from the day before surgery to the final follow-up on day 15 after surgery.

03

Conditions studied

  • Perioperative Neurocognitive Disorders
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥ 60 years, either sex; Scheduled for elective oral and maxillofacial surgery under general anesthesia (including oral and maxillofacial tumor surgery, orthognathic surgery, and maxillofacial trauma repair surgery); (ASA) physical status I-III; Expected duration of anesthesia ≥ 2 hours; Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

Pre-existing behavioral disorders or psychiatric diseases (e.g., Alzheimer's disease, Parkinson's disease), or current use of antipsychotic medications (e.g., clozapine, risperidone, olanzapine, haloperidol, chlorpromazine); Pre-existing severe organ dysfunction including: severe cardiovascular disease (life-threatening arrhythmias, severe uncontrolled hypertension, coronary artery disease, heart failure), severe respiratory disease (respiratory failure, severe ), severe hepatic insufficiency ( Class C), or severe renal insufficiency ( \< 30 mL/min or creatinine > 2.5 mg/dL); Known to esketamine including: to the active substance or any ; severe risk of elevated blood pressure or intracranial pressure; uncontrolled or untreated hypertension (resting systolic/diastolic blood pressure > 180/100 mmHg); preeclampsia or eclampsia; untreated or inadequately treated hyperthyroidism; conditions requiring uterine relaxation (e.g., uterine rupture, umbilical cord prolapse); use as the sole anesthetic in patients with significant ischemic heart disease; Surgical approach that would interfere with postoperative assessment; Concurrent participation in another clinical trial; Pre-existing cognitive impairment or Mini-Mental State Examination (MMSE) score \< 24, unable to complete questionnaire-based assessments.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Esketamine Group

    Participants in this arm will receive an intravenous bolus of esketamine 0.3 mg/kg (administered over 1 minute) after anesthesia induction, followed by a continuous infusion of 0.3 mg/kg/h, which will be discontinued 30 minutes before the end of surgery. The drug will be prepared in normal saline to a total volume of 10 mL and administered in a double-blind manner

    Drug: esketamine

  • Placebo comparator
    Normal Saline Group

    Participants in this arm will receive an equal volume of normal saline at the same time points as the experimental group: a bolus after anesthesia induction followed by a continuous infusion, which will be discontinued 30 minutes before the end of surgery. The placebo will be prepared in identical syringes to maintain blinding

    Drug: Normal Saline

Interventions

  • Esketamine is administered as an intravenous bolus of 0.3 mg/kg (over 1 minute) after anesthesia induction, followed by a continuous intravenous infusion of 0.3 mg/kg/h until 30 minutes before the end of surgery. The drug is diluted with normal saline to a total volume of 10 mL and prepared in identical syringes to ensure blinding. This intervention is used as the experimental treatment to assess its effect on postoperative cognitive recovery in elderly patients undergoing oral and maxillofacial surgery

  • DrugNormal Saline

    Normal saline is used as the placebo control. It is administered as an intravenous bolus of equal volume after anesthesia induction, followed by a continuous intravenous infusion at an equal rate until 30 minutes before the end of surgery. The saline is prepared in identical syringes to the experimental drug to maintain double-blind conditions. This intervention serves as the comparator to evaluate the specific effect of esketamine on postoperative cognitive recovery

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment (MoCA) Score on Postoperative Day 1

    Montreal Cognitive Assessment (MoCA) Score on Postoperative Day 1

    Time frame: Day 1 after surgery

Secondary outcomes

  1. Telephone-Montreal Cognitive Assessment (T-MoCA) Score at Postoperative Days 3, 7, and 15

    The Telephone-Montreal Cognitive Assessment (T-MoCA) is an adapted version of the MoCA designed for telephone administration, removing visual-dependent items. Total scores range from 0 to 22, with higher scores indicating better cognitive function. It will be administered by trained assessors blinded to group allocation at postoperative days 3, 7, and 15 to track cognitive recovery trajectory

    Time frame: Postoperative days 3, 7, and 15

  2. Sleep Quality Assessed by Athens Insomnia Scale (AIS) at Postoperative Days 1 and 3

    The Athens Insomnia Scale (AIS) is an 8-item self-report questionnaire assessing sleep quality over the past 24 hours. Total scores range from 0 to 24, with higher scores indicating worse sleep quality: 0-3 = no insomnia; 4-6 = mild insomnia; 7-10 = moderate insomnia; ≥11 = severe insomnia.

    Time frame: Postoperative days 1 and 3

  3. Pain Intensity Measured by Visual Analog Scale (VAS) at Postoperative Hours 6, 12, and 24

    The Visual Analog Scale (VAS) is a 10-cm horizontal line anchored by "no pain" at 0 and "worst imaginable pain" at 10. Patients mark their current pain level, and the distance from 0 is measured in millimeters. Scores range from 0 to 10, with higher scores indicating more severe pain.

    Time frame: Postoperative hours 6, 12, and 24

  4. Emotional Status Assessed by Hospital Anxiety and Depression Scale (HADS) at Postoperative Days 1 and 3

    The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report questionnaire with two subscales: anxiety (7 items) and depression (7 items). Each item is scored 0-3, with subscale scores ranging from 0 to 21. Higher scores indicate worse mood disturbance. Scores ≥11 on either subscale indicate clinically significant symptoms.

    Time frame: Postoperative days 1 and 3

  5. Incidence of Rescue Analgesia

    Rescue analgesia is defined as the administration of patient-controlled analgesia (PCA) pump when postoperative VAS score reaches ≥4. The incidence will be recorded and compared between groups

    Time frame: During the first 24 hours after surgery

  6. serological indicators

    Peripheral venous blood samples (3 mL) will be collected at baseline (1 day before surgery) and at 24 hours after surgery. Serum levels of inflammatory cytokine interleukin-6 (IL-6), neuronal injury marker S100β protein, brain-derived neurotrophic factor (BDNF), and neurofilament light chain (NfL) will be measured using enzyme-linked immunosorbent assay (ELISA). Correlations between biomarker changes and cognitive outcomes will be explored.

    Time frame: Baseline (1 day before surgery) and 24 hours after surgery

  7. incidence of adverse reactions

    Adverse events will be monitored from drug administration to 24 hours post-surgery, including: blood pressure fluctuations (MAP change \>20% from baseline), heart rate changes (HR \>100 bpm or \<50 bpm), psychiatric symptoms (hallucinations, dizziness, somnolence), and gastrointestinal reactions (nausea, vomiting with PONV impact scale ≥1). All adverse events will be recorded and compared between groups

    Time frame: From study drug administration to 24 hours after surgery

07

Study locations

1 site
  • The Third Affiliated Hospital of Air Force Medical University
    Xi'an, Shaanxi 710032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jan 2027, 6 months later.

Of 80 non-industry interventional studies with no phase under Neurocognitive Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 46. This study's planned 6 months is below that.

Counting every sponsor, half of 83 studies reached it within 27 months; a quarter within 15 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 24, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jan 31, 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07665099
Lead sponsor
Xijing Hospital
Responsible party
Zhang Haopeng (Chief Physician, Xijing Hospital) — Principal investigator
First posted
Jun 24, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Haopeng Zhang
Contact
haopeng.zhang@foxmail.com
+86 17791305967
Guanghui Hao
Contact
15291285018@163.com
+8615291285018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion